Bloomberg Audio Studios, podcasts, radio news, The.
Stock Movers Report, your roundup of companies making moves in the stock market, harnessing the power of Bloomberg Data.
Let's take a look at some of the stocks on the move today on Paul Swenya alongside Alexis Christopherus and we're joined by Bloomberg's Christina. You know, Christine, what are you looking at today? Well, well, let's talk about in Video because that is the one stock that is on
everybody's minds this morning. So ticker NVDA. Those shares are down more than two percent, two and a half percent at the moment, actually, and that is because we did get that reporting from the Financial Times saying that China's Internet regulator has told the country's biggest technology companies to stop buying in Vidia chips, specifically the rtx pro six thousand D chips. Now, this chip isn't regarded as among in Vidia's marquee products. It's more of a high end card.
They designed it specifically for the restricted Chinese market. But now we have this order from the Chinese authorities telling their biggest companies to not buy the jit We did get a report from the BBC quoting and Viga CEO Jensen Huang saying that he's quote disappointed by the ruling and that he would be quote patients in responding to it right. Also, Christine, General Mills, I guess benefiting from the fact that more folks are eating at home, they're eating out less.
But I'm looking at the stock, it's not doing much of anything right now.
Yeah, absolutely, Alexi sits down, So ticker gis General Mills shares down just a tenth of one percent at the moment. So clearly the first quarter adjusted EPs beat not doing much to lift that stock at the moment, but they did get that beat. It's eighty six cents topping analyst estimates. In the company was saying that is indeed the rise of home cooking among value conscious consumers that are struggling with inflation. That has helped some of their segments, including
rice and beans. But at the same time, there is kind of a warning in there. They did say that sales in North America retail segment dropped thirteen percent for the quarter to two point six billion, So that's probably people substituting in store brands for name brands.
I know, I am I know, I am and I am all of that the last four or five years.
Yeah, So that's probably why we're not getting much of a lift because there is it's a bit of a double edged sword kind of report from General Mills today. You spend generations building up brand value and then puff gone. That's what a little inflation will take. That's what a little inflation to do. L l y Eli Lilly, l y Eli Lilly. So those shares not up by much, just about to four tens of one percent at the moment. But they did get good news from a trial of
their golp one drug. It's an oral drug, experimental diabetes pill, which showed that people on this for the trial lost more weight and had a better blood sugar control than those in an older approved rival from Novo Nordisk. So this is a head to it drug trial. Patients that were given Eli Lilly's oral drug lost eight point two percent of their body weight in fifty two weeks versus five point three percent for the Novo drug. So doctors who were kind of they presented the results of doctors
and the doctors saying that the results look positive. They say that the tablet will make it possible to treat more patients because it's easier to produce and to take given that it is an oral drug.
The Stock Mover's report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street and for the latest market moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business app.